Pharmaceuticals, Biotechnology and Life Sciences
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment…
DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) — Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated…
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming…
●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would…
GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a…
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) — In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ:…
Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo,…
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova…
HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its…
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new “gold standard” outperforming…